An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater
- Alabama
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater
- Arizona
-
-
California
-
Los Angeles, California, Forenede Stater
- California
-
-
Colorado
-
Denver, Colorado, Forenede Stater
- Colorado
-
-
Florida
-
Bradenton, Florida, Forenede Stater
- Florida
-
Miami, Florida, Forenede Stater
- Florida
-
-
Illinois
-
Evanston, Illinois, Forenede Stater
- Illinios
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater
- Indiana
-
-
Massachusetts
-
Burlington, Massachusetts, Forenede Stater
- Massachusetts
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater
- Michigan
-
Detroit, Michigan, Forenede Stater
- Michigan
-
-
Missouri
-
St Louis, Missouri, Forenede Stater
- Missouri
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater
- Nebraska
-
-
New York
-
New York, New York, Forenede Stater
- New York
-
Rochester, New York, Forenede Stater
- New York
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater
- North Carolina
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater
- Ohio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater
- Pennsylvania
-
-
Texas
-
Dallas, Texas, Forenede Stater
- Texas
-
Houston, Texas, Forenede Stater
- Texas
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male and female participants between the ages of 18 and 65 years
- History of orthotopic liver transplantation less than 10 years before the Screening visit but no sooner than 6 months before Day 1
- Taking a stable immunosuppressant regimen based on either tacrolimus or cyclosporine without substantial dose changes over the past 3 months
- Naive to pegylated interferon/ribavirin treatment or experienced with pegylated interferon/ribavirin prior to transplantation with relapse, partial, or null response
Exclusion Criteria:
- Documented cirrhosis after liver transplantation
- Ascites or hepatic encephalopathy within 6 months before Screening
- Retransplantation for recurrent hepatitis C
- Treatment for hepatitis C post liver transplantation
- History within the past 3 months of: rejection within 3 months or greater than (>) 1 rejection within 12 months
- Current treatment with sirolimus or methylprednisolone. Low dose prednisone use (<5 milligram per day) is permitted
- History within 3 months of any bacterial infection requiring >1 week of intravenous antibiotics, cytomegalovirus viremia or cytomegalovirus infection with end-organ involvement, fungal disease (except cutaneous and mild oral thrush)
- History of post transplant lymphoproliferative disease
- Acceptable laboratory values at Screening as specified in the protocol
- Positive for human immunodeficiency virus 1/2 (HIV1/2) enzyme immunoassay (EIA) antibody screen or Hepatitis B deoxyribonucleic acid (DNA) or Hepatitis B surface antigen
- History of hepatocellular carcinoma with high risk of recurrence
- Any other cause of liver disease deemed clinically significant by the investigator in addition to hepatitis C
- Autoimmune-mediated disease
- History of acute pancreatitis within 5 years before the Screening visit
- Prior treatment with an hepatitis C virus (HCV) protease inhibitor
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: T/PR + Immunosuppressant Regimen (Tacrolimus)
Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
|
Tablet
Andre navne:
Tablet
Andre navne:
Subkutan injektion
Andre navne:
Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice.
Immunosuppressant regimen were not considered study drugs.
|
|
Eksperimentel: T/PR + Immunosuppressant Regimen (Cyclosporine)
Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
|
Tablet
Andre navne:
Tablet
Andre navne:
Subkutan injektion
Andre navne:
Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice.
Immunosuppressant regimen were not considered study drugs.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
Tidsramme: 12 weeks after last planned dose of study drug (up to Week 60)
|
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (<lower limit of quantification) at 12 weeks after last planned dose of study treatment.
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 international units per milliliter (IU/mL).
|
12 weeks after last planned dose of study drug (up to Week 60)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
Tidsramme: 24 weeks after last planned dose of study drug (up to Week 72)
|
SVR24 was defined as an undetectable HCV RNA Levels at 24 weeks after last planned dose of study treatment.
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL.
|
24 weeks after last planned dose of study drug (up to Week 72)
|
|
Percentage of Participants With Rapid Viral Response (RVR)
Tidsramme: Week 4
|
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.
RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.
|
Week 4
|
|
Percentage of Participants With Extended Rapid Viral Response (eRVR)
Tidsramme: Week 4 and Week 12
|
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.
eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment.
|
Week 4 and Week 12
|
|
Percentage of Participants With On-Treatment Virologic Failure
Tidsramme: Baseline up to Week 48
|
On-treatment virologic failure was defined as subjects who met futility or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks).
Data for this outcome was not planned to be reported by prior response.
|
Baseline up to Week 48
|
|
Percentage of Participants With Viral Relapse
Tidsramme: 48 weeks
|
48 weeks
|
|
|
Pharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)
Tidsramme: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants Requiring Dose Titration of Immunosuppressant Medications
Tidsramme: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants With Biopsy Confirmed and Treated Rejection
Tidsramme: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage
Tidsramme: 48 weeks
|
48 weeks
|
|
|
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
Tidsramme: 48 weeks
|
48 weeks
|
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Baseline up to Week 52
|
Any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not.
An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug.
SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
"Study drug" includes all investigational agents (including placebo, if applicable) administered during the course of the study.
|
Baseline up to Week 52
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percentage of Participants With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)
Tidsramme: 4 weeks after last planned dose of study drug (up to Week 52)
|
4 weeks after last planned dose of study drug (up to Week 52)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Leversygdomme
- Flaviviridae infektioner
- Hepatitis, viral, menneskelig
- Hepatitis
- Hepatitis C
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Antimetabolitter
- Antineoplastiske midler
- Immunologiske faktorer
- Interferoner
- Interferon-alfa
- Ribavirin
- Peginterferon alfa-2a
- Interferon alfa-2
- Immunsuppressive midler
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- VX11-950-117
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .